200 results on '"Vollbrecht, Claudia"'
Search Results
2. Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
3. DNA methylation-based classification of sinonasal tumors
4. Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids
5. Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
6. What’s New Liquid Biopsy – PIK3CA-Testung beim Mammakarzinom
7. cCPE Fusion Proteins as Molecular Probes to Detect Claudins and Tight Junction Dysregulation in Gastrointestinal Cell Lines, Tissue Explants and Patient-Derived Organoids
8. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
9. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation
10. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance
11. Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
12. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial
13. Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study
14. 2022-RA-873-ESGO Validation study of the ‘NOGGO-GIS ASSAY’ based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial
15. Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group
16. Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers
17. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis
18. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location‐dependent patterns of genetic and epigenetic alterations
19. NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?—Case series and review of the literature
20. Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients
21. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis
22. KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma
23. KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma
24. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium
25. Deep ion sequencing of amplicon adapter ligated libraries: a novel tool in molecular diagnostics of formalin fixed and paraffin embedded tissues
26. The Issue of Studies Evaluating Biomarkers Which Predict Outcome after Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma
27. Reduced Folate Carrier and Folylpolyglutamate Synthetase, but not Thymidylate Synthase Predict Survival in Pemetrexed-Treated Patients Suffering from Malignant Pleural Mesothelioma
28. Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma
29. Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options
30. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location‐dependent patterns of genetic and epigenetic alterations.
31. supplemental_table_2 - Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine Tumors
32. Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases
33. Multi institutional evaluation of a high sensitive NGS assay for liquid biopsy mutation detection in lung cancer
34. Mutational Analysis of Pulmonary Tumors with Neuroendocrine Features Using Targeted Parallel Sequencing
35. Multi institutional evaluation of a new NGS assay for mutation detection from cfDNA in lung cancer
36. Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma.
37. Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients
38. Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine Tumors
39. Liquid Biopsy in der Routine Diagnostik: Perspektiven und Grenzen
40. Abstract 5694: Multi institutional evaluation of a new NGS assay for mutation detection from cfDNA in lung cancer
41. Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
42. ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were Identified as Reference Genes in Neuroendocrine Lung Cancer via the nCounter Technology
43. Quality-assured analysis of PIK3CAmutations in HR+/HER2- breast cancer tissue – A story about the need for proficiency testing for high-quality molecular biomarker reporting in precision medicine
44. microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma
45. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas
46. miRNA-regulated pathways in neuroendocrine tumors of the lung
47. Evaluation of prognostically and therapeutically relevant genomic alterations in salivary gland carcinomas
48. mRNA biomarker screening in neuroendocrine pulmonary malignancies
49. MDM2andCDK4amplifications are rare events in salivary duct carcinomas
50. Folic acid phenotype (FAP) as superior marker to predict pemetrexed response in pleural mesothelioma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.